Product Images Clopidogrel Bisulfate

This appears to be a figure showing exposure to clopidogrel active metabolite following multiple doses of clopidogrel 75 mg alone or with proton pump inhibitors (PPIs). It also shows the effect of co-administered PPI on active metabolite AUC. However, the text is incomplete and doesn't provide much context.*

Figure 2 shows the occurrence of cardiovascular death, myocardial infarction, and stroke in the CURE study. The chart presents the cumulative event rate over a period of 12 months of follow up. The study compared the use of clopidogrel with aspirin and a placebo combined with other standard therapies. Clopidogrel with aspirin showed to have a significant reduction in the risk of cardiovascular events compared to placebo with aspirin.*

The text describes the results of the CURE study, showing hazard ratios for different patient baseline characteristics and concomitant medications/interventions. The hazard ratios are presented in a table format, with information on subgroup size, percentage of patients on clopidogrel and placebo, and the direction of the favorability of treatment. The table includes subgroups based on age, gender, race, elevated cardiac enzymes, diabetes, previous myocardial infarction, previous stroke, and concomitant medications such as heparin/LMWH, aspirin, GPIIb/IIIa antagonists, beta-blockers, and ace inhibitors.*

The text is a comparison between two treatments, Placebo and Clopidogrel, and their effectiveness in reducing mortality rate in patients up to 28 days after randomization. The data shows that 1845 out of the patients who received placebo (8.1%) died, while 1726 out of those who received Clopidogrel (7.5%) died. This indicates a proportional risk reduction of 7%. The data also suggests that Clopidogrel was more effective in reducing mortality, with a significant reduction seen after 54 days of discharge.*

This is a description of a study that likely involves two treatments, Placeho and Clopidogrel. The text provides information on the number of patients with an event (possibly a negative event related to the treatment), the percentage of patients with death, and the proportional risk of re-infarction reduction. There is a graph that shows the number of days since randomization and how many patients experienced an event within each time period. However, the details of the study are not clear and further information would be needed to fully understand the results.*

This appears to be a medical data table with several variables such as subgroup, age, gender, heart rate, and fibrinolytic agent given. The numbers in the table represent counts and percentages of individuals within each category. There is also a comparison of the effects of Clopidogrel and Placebo on certain outcomes. It is not possible to provide further insights without more context.*

The text describes a table showing the cumulative event rate percentage for fatal or non-fatal vascular events for two drugs: aspirin and clopidogrel. The table has four follow-up periods: 6, 12, 18, and 24 months. The symbol "@" is used to separate the two drugs, and "&" is used to separate the follow-up time points.*

This is a medication package containing a type of tablet called CLOP'DOGREL, which is round and pink-colored. Its dosage is 75mg and it should be stored at room temperature. The manufacturer seems to be ScieGen Pharmaceuticals Inc. and the pack contains 90 tablets. There are further instructions to keep all drugs out of reach of children. There is also some code mentioned on the pack - NDC 6362980451 08045901523487 - but its significance is not clear.*